Nature Communications (Nov 2022)

Regulome analysis in B-acute lymphoblastic leukemia exposes Core Binding Factor addiction as a therapeutic vulnerability

  • Jason P. Wray,
  • Elitza M. Deltcheva,
  • Charlotta Boiers,
  • Simon Е Richardson,
  • Jyoti Bikram Chhetri,
  • John Brown,
  • Sladjana Gagrica,
  • Yanping Guo,
  • Anuradha Illendula,
  • Joost H. A. Martens,
  • Hendrik G. Stunnenberg,
  • John H. Bushweller,
  • Rachael Nimmo,
  • Tariq Enver

DOI
https://doi.org/10.1038/s41467-022-34653-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 18

Abstract

Read online

The ETV6-RUNX1 chimeric- and native RUNX1-responsive regulomes in paediatric B-acute lymphoblastic leukemia (B-ALL) remain to be characterized. Here, the authors reveal functional antagonism between the two transcription factors predominantly for the regulation of cell cycle-associated pathways and dependency on native RUNX1 for tumorigenesis which can be targeted pharmacologically.